Molecules · 2015 · 11 citations · 28 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoverySynthetic Medicinal ChemistryAntibacterial PharmacologyMolecular DockingStructure-activity Relationship AnalysisAnticancer ActivityAnticancer Compound ScreeningAntimicrobial PropertiesChemical Structure-activity RelationshipsDihydrofolate Reductase TargetsDocking StudiesMedicinal Chemistry ApplicationsMolecular Docking Analysis
Suzuki-Miyaura cross-coupling of 6-bromo-2-styrylquinazolin-4(3H)-ones with arylboronic acids afforded a series of novel 6-aryl-2-styrylquinazolin-4(3H)-ones. These compounds were evaluated for potential anticancer properties against the human renal (TK-10), melanoma (UACC-62) and breast cancer (MCF-7) cell lines. Their antimicrobial properties were also evaluated against six Gram-positive and four Gram-negative bacteria, as well as two strains of fungi. Molecular docking studies (in silico) were conducted on compounds 5a, b, d and 6a, b, d-f to recognize the hypothetical binding motif of the title compounds within the active site of the dihydrofolate reductase and thymidylate synthase enzymes.
28
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Philip Skehan, Ritsa Storeng, Dominic A. Scudiero et al. · JNCI Journal of the National Cancer Institute · 1990 · 9.8K citations
Medicine, Oncology, Pharmacology +10
Synthesis of quinazolinones and quinazolines
David J. Connolly, Declan Cusack, Timothy P. O’Sullivan et al. · Tetrahedron · 2005 · 625 citations